ARDELYX, INC. Deferred Tax Liabilities, Gross
ARDELYX, INC. (ARDX) had Deferred Tax Liabilities, Gross of $1.20 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-19
- 2025-12-31: Deferred Tax Liabilities, Gross $1.20M.
- 2024-12-31: Deferred Tax Liabilities, Gross $598.00K.
- 2023-12-31: Deferred Tax Liabilities, Gross $1.36M.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $1.20M 10-K · filed 2026-02-19 |
| 2024-12-31 | $598.00K 10-K · filed 2026-02-19 |
| 2023-12-31 | $1.36M 10-K · filed 2025-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |